Clearmind advances recruitment for third cohort of CMND-100 trial at leading sites - BioTuesdays

Clearmind advances recruitment for third cohort of CMND-100 trial at leading sites - BioTuesdays

Clearmind Medicine (NASDAQ: CMND) has announced the continuation of participant enrollment for the third cohort of its ongoing FDA-approved Phase 1/2a trial evaluating CMND-100, its proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of alcohol use disorder (AUD). According to Clearmind, participant recruitment at leading sites—including Yale University, Johns Hopkins University, and Tel Aviv Sourasky Medical Center—…